Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Kinase inhibitors overachieve in CLL.

× No keyword cloud information.

6 in total

1. New quinoline/chalcone hybrids as anti-cancer agents: Design, synthesis, and evaluations of cytotoxicity and PI3K inhibitory activity.

Authors: Samar H Abbas; Amer Ali Abd El-Hafeez; Mai E Shoman; Monica M Montano; Heba A Hassan
Journal: Bioorg Chem Date: 2018-11-02 Impact factor: 5.275

2. Preventing clonal evolutionary processes in cancer: Insights from mathematical models.

Authors: Ignacio A Rodriguez-Brenes; Dominik Wodarz
Journal: Proc Natl Acad Sci U S A Date: 2015-07-21 Impact factor: 11.205

Review 3. The emerging role of mass spectrometry-based proteomics in drug discovery.

Authors: Felix Meissner; Jennifer Geddes-McAlister; Matthias Mann; Marcus Bantscheff
Journal: Nat Rev Drug Discov Date: 2022-03-29 Impact factor: 112.288

4. Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma.

Authors: Tracy C Okoli; Cody J Peer; Kieron Dunleavy; William D Figg
Journal: Cancer Biol Ther Date: 2015 Impact factor: 4.742

5. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.

Authors: G S Choudhary; S Al-Harbi; S Mazumder; B T Hill; M R Smith; J Bodo; E D Hsi; A Almasan
Journal: Cell Death Dis Date: 2015-01-15 Impact factor: 8.469

6. miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies.

Authors: Sayer Al-Harbi; Gaurav S Choudhary; Jey Sabith Ebron; Brian T Hill; Nagarajavel Vivekanathan; Angela H Ting; Tomas Radivoyevitch; Mitchell R Smith; Girish C Shukla; Alex Almasan
Journal: Mol Cancer Date: 2015-11-04 Impact factor: 27.401

6 in total